Why Immunovant Could Benefit From The J&J-Momenta Deal

Immunovant Inc IMVT shares were ripping higher Wednesday in a sympathy move.

What Happened: Shares of New York-based Immunovant, which focuses on treatment for autoimmune disorders, gap-opened Wednesday's session higher and were seen trading with notable gains.

This is despite a lack of any company-specific announcement.

The gains can be traced to a deal announced by Johnson & Johnson JNJ to buy another autoimmune diseases-focused biopharma, Momenta Pharmaceuticals, Inc. MNTA.

Momenta's lead drug nipocalimab is anti-FcRn antibody that is currently being developed in clinical programs for multiple autoimmune disorder indications.

Analyst Sees Positive Read-Through For Immunovant: The J&J-Momenta deal validates the anti-FcRn space, SVB Leerink analyst Thomas Smith said in a Wednesday note. 

The deal represents the first significant M&A investment in the class from a large pharma or biotech beyond Alexion Pharmaceuticals, Inc. ALXN, which had previously completed smaller licensing transactions for ALXN1830 and ABY-039, the analyst said. 

Immunovant's investigational product candidate IMVT-1401 is also an anti-FcRn antibody.

The validation of the substantial FcRn opportunity is likely to drive Immunovant shares higher, Smith said. 

SVB Leerink continues to see Immunovant as well-positioned to capitalize on increasing strategic interest in the class, given IMVT-1401's favorable attributes, which include competitive IgG lowering, a relatively clean safety/tolerability profile vs. the rest of the FcRn class and a subcutaneous injection formulation, the analyst said. 

SVB Leerink reiterated an Outperform rating on Immunovant with a $26 price target. 

IMVT Price Action: Immunovant shares were rallying 11.67% to $30.72 at the time of publication Wednesday. 

Related Links:

Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates

The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechM&APrice TargetReiterationAnalyst RatingsMoversTrading IdeasSVB LeerinkThomas Smith
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!